Skip to main content
S&P 5007,670.84-0.17%DOW51,349.92-0.26%NASDAQ26,797.54-0.09%GOLD$4,213.90+0.82%OIL$88.58-0.90%
Delayed
Smart Investors Daily
AR

NASDAQ · ARWR

Arrowhead Pharmaceuticals, Inc.

Healthcare · Biotechnology

$65.46

Up+$0.79 (+1.21%)

Updated Sep 29, 2026, 10:29 PM

SID Score

4.2/10

Composite research score

Smart Money

58/100

Neutral

Market cap
8.86B
P/E ratio
43.81
Dividend yield
0.00%
52-week range
$34.47 – $95.49
Volume
1.59M
Avg. volume
3.18M

Price performance · ARWR

ARWR price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Sep 28, 2026

ARWR closed at $65.46 after 20 trading sessions, down 20.55% for the selected period.

Last close
$65.46
Period change
-20.55%
Period low
$65.46
Period high
$86.49
Daily close
View OHLC price history
ARWR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 28, 2026$65.00$66.1133$63.99$65.461.59M
Sep 25, 2026$66.50$67.4381$65.40$65.921.62M
Sep 24, 2026$67.00$67.45$65.46$66.071.63M
Sep 23, 2026$72.155$72.49$66.27$66.962.56M
Sep 22, 2026$68.85$72.365$68.08$71.863.12M
Sep 21, 2026$67.455$69.26$66.06$68.792.35M
Sep 18, 2026$67.83$68.05$66.36$66.484.02M
Sep 17, 2026$68.91$68.91$66.995$67.743.21M
Sep 16, 2026$70.41$71.9283$64.50$65.795.11M
Sep 15, 2026$82.89$83.55$70.605$70.674.37M
Sep 14, 2026$82.98$83.27$79.93$80.671.33M
Sep 11, 2026$83.75$85.98$82.355$82.851.34M
Sep 10, 2026$81.58$83.38$80.33$82.761.02M
Sep 9, 2026$84.65$87.20$82.16$82.633.67M
Sep 8, 2026$84.22$86.96$83.54$85.111.57M
Sep 4, 2026$85.87$86.96$84.2042$86.34757.85K
Sep 3, 2026$85.18$86.79$83.46$86.491.37M
Sep 2, 2026$82.87$85.47$82.085$85.371.53M
Sep 1, 2026$81.14$83.27$80.76$82.741.33M
Aug 31, 2026$83.13$83.7554$80.75$82.391.6M

Latest ARWR news

The latest Smart Investors Daily articles mentioning ARWR.

Stock researchCompany · Overview

Company

OverviewForecastEarnings — requires Earnings Calls and Results accessDividend — requires Dividend Research accessFinancials

Market Activity

OptionsInsider Trades — requires Insider Buying and Selling accessShort InterestInstitutional Ownership — requires Institutional Ownership accessSentiment

ARWR research

Overview

Company profile and research snapshot.

Company profile

Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$71.00
Implied upside
—
Analysts
—
ARWR recent ratings
DateFirmRatingTarget
Sep 24, 2026Goldman SachsNeutral—
Sep 8, 2026CitigroupBuy—
Sep 1, 2026HC Wainwright & Co.Buy—
Aug 31, 2026RBC CapitalOutperform—
Aug 31, 2026Chardan CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Feb 27, 2026

Alpha-1 Antitrypsin Deficiency Research Report 2025-2035: Market Enters Growth Phase as Established Augmentation Therapies Converge with Advancing Gene and RNA Pipelines

Alpha-1 Antitrypsin Deficiency (AATD) is a rare genetic disorder caused by SERPINA1 gene mutations, leading to conditions like pulmonary emphysema and liver dysfunction. The AATD market is in its growth stage, fueled by increased R&D in protein augmentation, gene therapies, and rising awareness. Established treatments include intravenous augmentation therapy, with inhaled formulations and emerging gene-editing therapies in development. North America leads the market thanks to strong infrastructu

Yahoo · Feb 18, 2026

Morgan Stanley Notes 2026 Sales From Arrowhead Pharmaceuticals, Inc. (ARWR)’s Familial Chylomicronemia Syndrome Likely Limited

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is among the 15 Innovative Healthcare Stocks to Buy According to Analysts. The tenth stock on our list is Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR). TheFly reported on February 6 that Morgan Stanley lowered its price target for ARWR to $78 from $81 and kept an Equal Weight rating. The firm noted that […]

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By